Year: 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Month: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
May 01, 2007
With the growth of the biotech industry and the maturing of the first breakthrough inventions, litigation over patents is becoming more frequent and spreading around the world. MIP has selected five important cases from the US, Australia, France and Germany that highlight some of the issues that have arisen in the past year. Emma Barraclough, James Nurton and Peter Ollier look at how the cases developed, and why they are significant for the industry
The US has, until now, been the preferred habitat of the patent troll. But assertive licensing companies are becoming increasingly aware of how they can use Europe's fragmented system of patent rules to their negotiating advantage, explain William Cook and Dafydd Bevan
How you prosecute a patent can affect how enforceable the right is. Blayne Peacock and Tim Watkin explain why legal changes in Singapore could mean that applicants face unexpected consequences if they try to patent on the cheap in one of Asia's burgeoning R&D centres
English courts are known for being thorough, but that can be expensive for litigants. Brian Whitehead, Stuart Jackson and Richard Kempner examine ways you can reduce the costs
The US Supreme Court decision in MedImmune gave licensees the right to challenge a licensed patent while continuing to pay royalties. But those patent owners that are responding to the new challenge by redrafting their licences must pay close attention to EU competition rules, say Sangeeta Puran and David Fyfield
Biotech inventors operate at the cutting-edge of technology, so they depend on strong and predictable IP protection. But is the IP system (including patent offices, courts, attorneys, lawyers) letting them down?
The European Commission has finally published its blueprint for an EU-wide patent strategy
A company at the heart of the controversy over compulsory licensing for pharmaceuticals in Thailand is to reduce the price it charges for one of its key drugs
Tax incentives on patent income are at the centre of debate in the EU after the European Commission told Ireland that it must change the way that it taxes patent royalties or face legal action
Has the US Congress found a way through competing interests to develop patent reform proposals that will satisfy everyone?
Deals between patent owners and open source distributors using the GNU General Public Licence version 3 would be blocked if the latest draft of the GPL is adopted
Patent protection for a new dosage regime of a known drug is now available in New Zealand after a decision by the assistant commissioner of patents
Switching to MIP International